Bristol-Myers Squibb Co (BMY)
22 Oct 2014
|Market Cap (Mil.):||$86,128.15|
|Shares Outstanding (Mil.):||1,657.91|
LONDON - ConvaTec's owners have appointed Morgan Stanley and Goldman Sachs to explore a sale of the medical device maker which could be worth up to $10 billion, sources familiar with the matter said.
LONDON, Oct 15 - ConvaTec's owners have appointed Morgan Stanley and Goldman Sachs to explore a sale of the medical device maker which could be worth up to $10 billion, sources familiar with the matter said.
NEW YORK - Bristol-Myers Squibb Co on Tuesday said it is no longer seeking U.S. approval for an oral two-drug combination to treat hepatitis C because of competition from rival drugs that require treatment for half as long and have shown higher cure rates.
(Adds comment from Bristol-Myers and analyst, adds background, updates shares)
- Bristol-Myers Squibb said it withdrew its U.S. marketing application for an oral drug combination to treat hepatitis C, citing a "rapidly evolving" treatment landscape in the country.
Oct 7 - Bristol-Myers Squibb said it withdrew its U.S. marketing application for a drug combination to treat hepatitis C.
ZURICH, Oct 6 - Swiss pharma group Novartis AG said on Monday it would work with Bristol-Myers Squibb Co to test the U.S. drugmaker's immuno-oncology drug Opdivo in combination with three of its own experimental lung cancer drugs.
ZURICH, Oct 6 - Swiss pharma group Novartis AG said on Monday it had entered into a clinical collaboration with Bristol-Myers Squibb Co to evaluate the safety and efficacy of combination treatments for patients with non-small cell lung cancer.
MADRID - Bristol-Myers Squibb's immunotherapy drug Opdivo produced markedly improved response rates with fewer toxic side effects compared to chemotherapy in a major melanoma study, underscoring its potential as a new treatment option.
* 32 percent response rate in patients treated with Opdivo
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (BMY). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.